Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 385 people in the simeprevir group and 386 people in the telaprevir group — a total of 771 participants — all of whom had hepatitis C. The trial was comparing two different antiviral medicines (simeprevir and telaprevir), each given alongside two other standard medicines (peginterferon alfa-2a and ribavirin). The main thing the trial was measuring was whether the hepatitis C virus became undetectable in participants' blood and stayed that way for at least 12 weeks after treatment finished — a result known as SVR12 (sustained virologic response at 12 weeks). The reported data shows that 53.6% of participants in the simeprevir group and 54.7% in the telaprevir group met the SVR12 measure — meaning the virus was undetectable in their blood at that point. For a similar measure taken 24 weeks after treatment ended (SVR24), the reported figures were 53.3% for the simeprevir group and 55.2% for the telaprevir group. The trial also tracked how many participants had the virus return after initially becoming undetectable — this is called viral relapse. The reported data shows a relapse was recorded in 17.9% of the simeprevir group and 16.4% of the telaprevir group. It is worth noting that 32 people in the simeprevir group and 36 in the telaprevir group did not complete the study, though the reasons for this were not detailed in the data provided here. No other outcome figures beyond those described above were included in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25482330) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have had a liver biopsy before or around the time of screening, unless a biopsy is not possible for you or you have signs of increased blood pressure in the liver not caused by scarring — in those cases, a recent (within 6 months) non-invasive liver scan or blood test result is needed instead
- You must have had hepatitis C for at least 6 months, confirmed by a blood test showing hepatitis C antibodies and/or the virus itself, or by scarring seen on a liver biopsy
- You must have the specific "genotype 1" strain of hepatitis C, with a virus level above 10,000 IU/mL in your blood — both confirmed at screening
- You must have already tried at least one full course of a specific combination treatment (pegylated interferon alfa-2a or alfa-2b with ribavirin) for at least 12–20 weeks, depending on how your body responded to it
Who may not be able to join:
- People whose liver is no longer functioning well, shown by significant abnormal test results or other active liver-related health problems
- People who also have HIV, or who have a strain of hepatitis C other than genotype 1
- People whose liver disease is caused by something other than hepatitis C
- People who have previously been treated for hepatitis C with anything other than pegylated interferon and ribavirin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tibotec Pharmaceuticals Limited Clinical Trial, Tibotec Pharmaceutical Limited
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.